- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval November 21, 2016).
- Why 3/10
- Xultophy is an already-approved, marketed drug (FDA approved November 2016) with no pending PDUFA, pivotal readout, or regulatory decision scheduled in the next 12 months. It is a small part of Novo Nordisk's massive diabetes portfolio, which is dominated by semaglutide products. The impact score is 3 because the drug is commercialized with no binary catalyst ahead.
Xultophy is an approved, marketed drug with no upcoming binary catalyst. The key event to watch is the projected loss of exclusivity around November 2028, which could open the door to biosimilar competition. For Novo Nordisk investors, Xultophy is a minor product within a portfolio dominated by semaglutide (Ozempic, Wegovy, Rybelsus); any material news would likely come from the broader GLP-1 competitive landscape or patent challenges rather than Xultophy-specific developments.
Price Chart
Executive Summary
Xultophy (insulin degludec and liraglutide, also known as IDegLira) is a once-daily fixed-ratio combination injectable for adults with type 2 diabetes, developed and marketed by Novo Nordisk (NVO). The FDA approved it in November 2016. It combines Tresiba (insulin degludec) with Victoza (liraglutide) in a single pen. As an already-approved, commercially established product with no pending regulatory catalysts, Xultophy is a mature asset within Novo Nordisk's vast diabetes portfolio. The company's investor focus is overwhelmingly on its semaglutide franchise (Ozempic, Wegovy, Rybelsus) and the newly launched oral Wegovy pill. Xultophy faces direct competition from Sanofi's Soliqua and is projected to face biosimilar competition around late 2028 when exclusivity expires.
How It Works
Xultophy is a once-daily injection that combines two diabetes medicines in one pen: insulin degludec (a long-acting insulin that provides steady blood-sugar control over 24 hours) and liraglutide (a GLP-1 receptor agonist that mimics a natural hormone to help the pancreas release insulin when blood sugar is high, slow digestion, and reduce appetite). It is used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Trial Status
Xultophy was approved by the FDA on November 21, 2016, following a 16-0 advisory committee vote in favor. It has been commercially available in the U.S. since early 2017 and is also approved in numerous other markets. No new pivotal trials are ongoing for this combination product.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalysts: Xultophy is an approved, marketed drug with no pending FDA decision or pivotal readout.
- Longer-term: Projected loss of exclusivity around November 2028, which could enable biosimilar entry.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report